Cost-effectiveness comparison of capecitabine combined with docetaxel versus docetaxel combined with epirubicin in the treatment of metastatic breast cancer

WU Liqing

doi:10.13919/j.issn.2095-6274.2019.11.011

Home>Articles>Cost-effectiveness comparison of capecitabine combined with docetaxel versus docetaxel combined with epirubicin in the treatment of metastatic breast cancer

DOI: 10.13919/j.issn.2095-6274.2019.11.011

Cost-effectiveness comparison of capecitabine combined with docetaxel versus docetaxel combined with epirubicin in the treatment of metastatic breast cancer

WU Liqing

Machine-generated Keywords：

Publication Date：2019-01-01

Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)

Pages：3( 640-642 )

Chinese Journal of Disaster Medicine

ISSN：2095-6275

Year, Vol.(Issue)：2019,7(11)